@prefix this: <http://purl.org/np/RAiDNaBIhanAn_80pA1Iw-TCIshFcuS9zN-XJ4wpsu3CQ> .
@prefix sub: <http://purl.org/np/RAiDNaBIhanAn_80pA1Iw-TCIshFcuS9zN-XJ4wpsu3CQ#> .
@prefix schema: <https://schema.org/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix dct: <http://purl.org/dc/terms/> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix nt: <https://w3id.org/np/o/ntemplate/> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix orcid: <https://orcid.org/> .
@prefix bl: <https://w3id.org/biolink/vocab/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix npx: <http://purl.org/nanopub/x/> .

sub:Head {
  this: np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:pubinfo;
    a np:Nanopublication .
}

sub:assertion {
  <http://purl.obolibrary.org/obo/DOID_13550> bl:category bl:Disease .
  
  sub:association rdf:object <http://purl.obolibrary.org/obo/DOID_13550>;
    rdf:predicate bl:treats;
    rdf:subject <https://identifiers.org/drugbank:DB00747>;
    a rdf:Statement;
    rdfs:label "\"Transderm Scop is contraindicated in the following populations:   Patients with angle closure glaucoma. [ see Adverse Reactions (6)] Persons who are hypersensitive to the drug scopolamine or other belladonna alkaloids or to any ingredient or component in the formulation or delivery system. [see  Drug Interactions (7) Description (11)   Patients with angle closure glaucoma ( 4 6.2 Persons who are hypersensitive to scopolamine or to other belladonna alkaloids ( 4 7\"";
    bl:provided_by <https://w3id.org/um/NeuroDKG>;
    bl:relation schema:MedicalContraindication .
  
  <https://identifiers.org/drugbank:DB00747> bl:category bl:Drug .
}

sub:provenance {
  sub:assertion prov:wasAttributedTo orcid:0000-0002-1468-3557 .
}

sub:pubinfo {
  sub:sig npx:hasAlgorithm "RSA";
    npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB";
    npx:hasSignature "Pui3dnUHjZJvL1nGaibMRlKMe99gbyh7siVMli/+wx8R0uWx95ZSyvb0r8khENAg7cntu9v+S5v1bZgIk5zzqiTzZyTmSOxItHox29nHmY1duZlvQdFrr9MSAII8tLxp9l+Ayqz/xnatlo9FWP40Hmxc424Hn7t7hCDD2wjCpd4=";
    npx:hasSignatureTarget this: .
  
  this: dct:created "2021-08-25T14:24:27.593+02:00"^^xsd:dateTime;
    dct:creator orcid:0000-0002-1468-3557;
    nt:wasCreatedFromProvenanceTemplate <http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM>;
    nt:wasCreatedFromPubinfoTemplate <http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM>;
    nt:wasCreatedFromTemplate <http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY> .
}